

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |  |   |
|---|--|--|---|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>C07H 17/08, A61K 31/70</b>   |  | <b>A1</b>  | <b>(11) International Publication Number:</b> <b>WO 96/19489</b><br><b>(43) International Publication Date:</b> 27 June 1996 (27.06.96) |
| <b>(21) International Application Number:</b> PCT/IE95/00065<br><b>(22) International Filing Date:</b> 19 December 1995 (19.12.95)<br><b>(30) Priority Data:</b><br>940973 19 December 1994 (19.12.94) IE<br><b>(71) Applicant (for all designated States except US):</b> RUSSINSKY LIMITED [IE/IE]; 90 South Mall, Cork (IE).<br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> SCHICKANEDER, Helmut [DE/IE]; "Dunhamon", South Douglas Road, Cork (IE). NIKOLOPOULOS, Aggelos [DE/IE]; Apartment No. 3 Sydenham, Off Wellington Road, Cork (IE). KELLY, Declan [IE/IE]; Ringacoltie, Rushbrooke, Cobh, County Cork (IE).<br><b>(74) Agents:</b> O'CONNOR, Donal, H. et al.; Cruickshank & Co., 1 Holles Street, Dublin 2 (IE). |  | <b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DE (Utility model), DK, DK (Utility model), EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).<br><br><b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |   |
| <b>(54) Title:</b> COMPOUNDS<br><br><b>(57) Abstract</b><br><br>Antibiotic and mucolytic salts of roxithromycin, clarithromycin and azithromycin are described. Particularly described is roxithromycin stinoprate which was found to be more potent than erythromycin stinoprate.  |  |  |   |

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria                  | GB | United Kingdom                        | MR | Mauritania               |
| AU | Australia                | GE | Georgia                               | MW | Malawi                   |
| BB | Barbados                 | GN | Guinea                                | NE | Niger                    |
| BE | Belgium                  | GR | Greece                                | NL | Netherlands              |
| BF | Burkina Faso             | HU | Hungary                               | NO | Norway                   |
| BG | Bulgaria                 | IE | Ireland                               | NZ | New Zealand              |
| BJ | Benin                    | IT | Italy                                 | PL | Poland                   |
| BR | Brazil                   | JP | Japan                                 | PT | Portugal                 |
| BY | Belarus                  | KE | Kenya                                 | RO | Romania                  |
| CA | Canada                   | KG | Kyrgyzstan                            | RU | Russian Federation       |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CG | Congo                    | KR | Republic of Korea                     | SE | Sweden                   |
| CH | Switzerland              | KZ | Kazakhstan                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LI | Liechtenstein                         | SK | Slovakia                 |
| CM | Cameroon                 | LK | Sri Lanka                             | SN | Senegal                  |
| CN | China                    | LU | Luxembourg                            | TD | Chad                     |
| CS | Czechoslovakia           | LV | Latvia                                | TG | Togo                     |
| CZ | Czech Republic           | MC | Monaco                                | TJ | Tajikistan               |
| DE | Germany                  | MD | Republic of Moldova                   | TT | Trinidad and Tobago      |
| DK | Denmark                  | MG | Madagascar                            | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                  | US | United States of America |
| FI | Finland                  | MN | Mongolia                              | UZ | Uzbekistan               |
| FR | France                   |    |                                       | VN | Viet Nam                 |
| GA | Gabon                    |    |                                       |    |                          |

- 1 -

"Compounds"Introduction


The present invention relates to new antibiotic and mucolytic salts of roxithromycin, clarithromycin and azithromycin.

5 The exploitation of the therapeutical properties of thiolic compounds in combination with the properties of antibiotics has been attempted as described in EP 0,057,489A. However, it has been found that acetyl-  
10 cysteine and the derivatives thereof are relatively unstable and especially sensitive to oxygen, sunlight, humidity and heat.

The invention is directed towards providing antibiotic and mucolytic salts.

Statements of Invention

15 The derivatives according to the present invention have the following general formula :



wherein R is a radical selected from :

Roxithromycin, Clarithromycin and Azithromycin.


20 It has been surprisingly found that the compounds of the present invention are very stable, have very low toxicity and can be therapeutically used once daily.

- 2 -


These new derivatives of the below mentioned macrolides have the further advantages of :-

- 5 (a) better oral absorption;  
(b) faster and superior concentration;  
(c) slow elimination; and/or  
(d) reduced dosage : only 300 - 500 mg per day.


Roxithromycin has the structure



Clarithromycin has the structure



Azithromycin has the structure



The compounds according to the invention are white microcrystalline powders.

5        Their use is foreseen in all pharmaceutical forms and the compounds may be provided in any suitable pharmaceutical composition including : capsules; solutions; injectable preparations; aerosols; effervescent tablets; powders; creams; and suspensions. The pharmaceutical compositions will typically contain suitable excipients and/or vehicles  
10        which are conventionally used in galenical pharmacy.

The method for the preparation of the new salts comprises reacting roxithromycin, clarithromycin or azithromycin base with N-acetylcystein in a stoichiometrical ratio or preferably with a slight excess of the antibiotic nucleus. Most preferably the reaction is carried out in an organic solvent, at a temperature of between 20 and 40°C and in the presence of water, preferably in an amount of not greater than 20%. Alternatively, the reactions may be carried out in a suspension of water at a temperature of 20 and 40°C, (with N-acetylcystein in a stoichiometrical ratio or in

- 4 -

the presence of a slight excess of the antibiotic nucleus), and after building the salts, water is distilled off under very mild conditions (low vacuum, low temperature).

5     Example

Salt of roxithromycin with N-acetylcystein

1800 g of Roxithromycin and 350.9 g of N-acetylcystein are homogenised under inert conditions (nitrogen) for 60 minutes at 15-20°C. To this mixture 720 ml of deionised  
10     water is added at atmospheric pressure and further homogenised for one hour at 15-20°C. The product is dried under vacuum and milled, if necessary. A yield of 79.8% (1716 g) is obtained.

15     The Infra Red spectrum of the compound is plotted in Fig. 1.

The salts of clarithromycin and azithromycin are produced in a similar manner to that described in the above example.

MICROBIOLOGICAL ASSAY OF ROXITHROMYCIN STINOPRATE

20     References: USP 23 <81> Antibiotics-Microbial Assays, page 1690-1696 Code of Federal Regulations Title 21 :436.100 - 436.106

Test Organism:

25     Staphylococcus aureus ATCC 29737  
The test organism was maintained through periodic inoculations on agar slants containing USP 23 Medium No. 1. The slants are incubated at 32-35°C for 24 hours, and

- 5 -

stored under refrigeration.

Assay Receptacles:

5 Sterile plastic petri-dishes (ca. 20 x 100mm) with covers were used as assay plates. Assay cylinders were manufactured from stainless steel (o.d. 8mm  $\pm$  0.1mm, i.d. 6mm  $\pm$  0.1mm, length 10mm  $\pm$  0.1mm).

Inoculum Preparation:

10 Using 5ml of sterile USP Saline T.S. the growth from an agar slant of S.aureus was washed and made up to 50ml with sterile saline solution. This stock suspension was diluted with sterile saline so that the transmittance, at 580nm, was 25% against  
15 saline as the blank.

1ml of this solution (i.e. giving 25% transmission) was added to each 100ml of culture media (USP 23 Medium No. 1 (Oxoid Antibiotic Medium No. 1)).

20 Culture Medium:

Oxoid Antibiotic Medium No. 1.

Solutions: Saline Solution (sterile)

|                 |       |
|-----------------|-------|
| Sodium chloride | 0.9g  |
| Purified Water  | 100ml |

25 Sterilised at 121°C for 20 minutes.

Buffer Solution No. 3 (USP 23)

|  |        |
|--|--------|
| (0.1M potassium phosphate buffer pH 8.0) |        |
| Dibasic potassium phosphate              | 16.73g |
| Monobasic potassium phosphate            | 0.523g |

- 6 -

Purified Water 1000ml

Adjusted with 10N potassium hydroxide to give a pH 7.9-8.1. Sterilised at 121°C for 20 minutes.

5 Standards: Erythromycin Stinoprate Standards:

10 About 100mg of Erythromycin Stinoprate standard, accurately weighed, was added to a 100ml volumetric flask. 10ml of methanol was added to dissolve the Erythromycin Stinoprate. This solution contains 10mg/ml of Erythromycin Stinoprate. A 1:10 dilution of this solution was then prepared with sterile buffer solution to obtain a 1000 µg/ml Erythromycin Stinoprate solution.

15

From this stock solution the following dilutions were prepared:

20 1.56 µg/ml ( $S_5$ ); 1.25 µg/ml ( $S_4$ ); 1.0 µg/ml ( $S_3$ ); 0.8 µg/ml ( $S_2$ ); and 0.64 µg/ml ( $S_1$ ) (using sterile buffer solution for dilutions)

Test Sample (Roxithromycin Stinoprate):

25 About 100mg of Roxithromycin embonate test substance, accurately weighed, was added to a 100ml volumetric flask. 10ml of methanol was added for dissolution and this in turn was diluted with sterile buffer solution to obtain a 1000 µg/ml Roxithromycin Stinoprate solution.



- 7 -

From this stock solution a solution was prepared containing 1.0 µg/ml Roxithromycin Stinoprate, using sterile buffer solution for dilution purposes (U<sub>3</sub>).

Method:

Cylinder-Plate Method USP 23 <81>

Approximately 20ml of sterilised Oxoid Antibiotic Medium No. 1 was placed in each of 22 sterile petri-dishes, and allowed to harden. Using the inoculum described above 5.0ml of seed layer inoculum were added to each plate except two plates which were reserved as "negative controls". Six (6) stainless-steel assay cylinders were dropped on the inoculated surfaces of 18 of the plates from a height of 12mm, with even spacing on a radius of 28mm. The remaining two inoculated plates were retained as positive controls.

Using a 1-level assay with standard curve, alternate cylinders on each of three plates were filled with the 1.0 µg/ml solution of Erythromycin Stinoprate (S<sub>3</sub>), and each of the remaining nine cylinders were filled with one of the four other dilutions of the Standard (S<sub>1</sub> - S<sub>5</sub>). This process was repeated for the other three dilutions of the standard.

The 1.0 µg/ml solution of Erythromycin Stinoprate (S<sub>3</sub>) was filled into alternate cylinders on each of three plates and

- 8 -

the remaining nine cylinders were filled with the Test Sample ( $U_3$ ).

Incubation: 24 hours at 32-35°C

Estimation of Potency:

5                   The potency of the Roxithromycin  
                    Stinoprate test substance was compared  
                    to the standard curve obtained for the  
                    Erythromycin Stinoprate standard  
10                   dilutions. This was calculated as a  
                    percentage of the potency of the 1.0  
                    µg/ml Erythromycin Stinoprate standard  
                    dilution.


Results:           Roxithromycin Stinoprate

15                   Mean potency ( $\bar{x}$ ) = 114% (of Erythromycin  
                    Stinoprate).  
                    Standard deviation (s.d.) = 2.94%.  
                    Coefficient of variation (c.v.) = 2.56%.

20                   The invention is not limited to the embodiments  
                    hereinbefore described which may be varied in detail.

**CLAIMS**


1. A compound of the formula



wherein R is a radical selected from :

Roxithromycin, Clarithromycin and Azithromycin.

- 5    2. N-Acetylcystein-Roxithromycin Salt.
3. N-Acetylcystein-Clarithromycin Salt.
4. N-Acetylcystein-Azithromycin Salt.
5. A compound substantially as hereinbefore described with reference to the examples.
- 10 6. A pharmaceutical composition comprising a compound as claimed in any preceding claim together with at least one pharmaceutically acceptable excipient and/or carrier.
7. A process for preparing a compound of the formula



- 10 -

wherein R is a radical selected from :

Roxithromycin, Clarithromycin and Azithromycin.

comprising the step of reacting N-Acetylcystein  
with roxithromycin, clarithromycin or azithromycin  
base.

5

8. A process as claimed in claim 7 wherein the  
reaction is carried out in an organic solvent.

9. A process as claimed in claim 7 or 8 wherein the  
reaction is carried out in an aqueous medium.

10 10. A process as claimed in any of claims 7 to 9  
wherein the reaction is carried out at a  
temperature of from 20°C to 40°C.

11. A process substantially as hereinbefore described  
with reference to the Examples.

15 12. A compound whenever prepared by a process as  
claimed in any of claims 7 to 11.




Fig. 1

## INTERNATIONAL SEARCH REPORT

Internatic Application No

PCT/IE 95/00065

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07H17/08 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| Y          | EP,A,0 057 489 (REFARMED RECH PHARM MED)<br>11 August 1982<br>cited in the application<br>see the whole document<br>---  | 1-12                  |
| Y          | INT. J. CLIN. PHARMACOL. THER. TOXICOL.,<br>vol. 26, 1988,<br>pages 444-7, XP002002013<br>M. DE BERNARDI ET AL.: "Human<br>pharmacokinetics of erythromycin<br>propionate-N-acetylcysteinate"<br>see the whole document<br>---<br>-/-- | 1-12                  |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents:

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "O" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

\* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\* "&" document member of the same patent family

Date of the actual completion of the international search

8 May 1996

Date of mailing of the international search report

30-05-1996

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Bardili, W

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IE 95/00065

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT.

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| Y          | EUR. J. RESPIR.,<br>vol. 1, 1988,<br>pages 171-5, XP002002014<br>O. PAULSEN ET AL.: "No effect of oral<br>N-acetylcysteine on the bioavailability of<br>erythromycin and bacampicillin"<br>see the whole document<br>---                  | 1-12                  |
| Y          | ANNAL. PHARMACOTHER.,<br>vol. 26, 1992,<br>pages 46-55, XP002002015<br>N. BAHAL AND M.C. NAHATA: "The new<br>macrolide antibiotics: azithromycin,<br>clarithromycin, dirithromycin and<br>roxithromycin"<br>see the whole document<br>--- | 1-12                  |
| Y          | J. CLIN. MICROBIOL.,<br>vol. 5, 1977,<br>pages 58-61, XP002002481<br>M.F. PARRY AND H. NEU: "Effect of<br>N-Acetylcysteine on Antibiotic Activity<br>and Bacterial Growth In Vitro"<br>see the whole document<br>---                      | 1-12                  |
| A          | FR,A,2 534 588 (ROUSSEL-UCLAF) 20 April<br>1984<br>see the whole document<br>-----  | 1-12                  |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No

PCT/IE 95/00065

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| EP-A-0057489                              | 11-08-82            | FR-A- 2502627              | 01-10-82            |
|   |                     | AT-T- 11546                | 15-02-85            |
|   |                     | EP-A,B 0060573             | 22-09-82            |
|   |                     | EP-A,B 0174395             | 19-03-86            |
|   |                     | JP-C- 1665945              | 29-05-92            |
|   |                     | JP-B- 3017840              | 11-03-91            |
|   |                     | JP-A- 57176996             | 30-10-82            |
|   |                     | JP-C- 1594100              | 14-12-90            |
|   |                     | JP-B- 2016320              | 16-04-90            |
|   |                     | JP-A- 57176997             | 30-10-82            |
|   |                     | JP-C- 1593607              | 14-12-90            |
|   |                     | JP-B- 2016758              | 18-04-90            |
|   |                     | JP-A- 60132999             | 16-07-85            |
|   |                     | US-A- 4393053              | 12-07-83            |
| -----                                     |                     |                            |                     |
| FR-A-2534588                              | 20-04-84            | NONE                       |                     |
| -----                                     |                     |                            |                     |



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**